Hemispherx Biopharma to Provide Update On Global Pandemic Influenza Prevention / Treatment Initiatives

Hemispherx Biopharma to Provide Update On Global Pandemic Influenza Prevention / Treatment Initiatives

PHILADELPHIA, July 20, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE AMEX:HEB) will provide an update on its Influenza research initiatives via teleconference on Wednesday, July 22, 2009, at 10:00 AM EDT. Initiatives to be discussed will include experimental programs planned or underway in Pacific Rim countries, Australia, South America and the United States. Background information may be sourced at Wall Street Journal, July 18/19, 2009, p. A3.

Hemispherx's Medical Director, CEO, and the Managing Director of the Sage Group, a health care consulting firm retained by Hemispherx, will participate. Investigational products and protocols to be discussed will include Hemispherx's Ampligen(r) (poly I: poly C12U), Alferon N (a natural cocktail of alpha 2 type interferons, FDA approved for treatment of refractory HPV) and Alferon LDO, an experimental formulation of Alferon-N for oral delivery.

 To access the conference call:
 U.S. Callers: 800-346-7359
 International Callers: 973-528-0008
 Conference Entry Code: 27781

This call will be webcast via the Company's website at: http://www.hemispherx.net.

 A digital replay of the call will be available until August 5, 2009
 by calling:
 U.S. Callers: 800-332-6854
 International Callers: 973-528-0005
 Conference Entry Code: 27781

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is a specialty pharma company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(r) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics, Ampligen(r) and Oragens. Ampligen(r) and Oragens represent experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 50 issued patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(r)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(r), Alferon LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(r) do not imply that the product will ever be specifically approved commercially for these other treatment indications; similarly, the completion of the NDA filing process with Ampligen(r) does not imply that the product will ever be approved commercially.